Skip to main content
Marker Therapeutics, Inc. logo

Marker Therapeutics, Inc. — Investor Relations & Filings

Ticker · MRKR ISIN · US57055L1070 US Manufacturing
Open in API
Filings indexed 899 across all filing types
Latest filing 2005-10-12 Board/Management Inform…
Country US United States of America
Listing US MRKR

About Marker Therapeutics, Inc.

https://markertherapeutics.com/

Marker Therapeutics, Inc. is a clinical-stage immuno-oncology company developing next-generation T cell-based immunotherapies for hematologic malignancies and solid tumors. The company's core technology is its Multi-Antigen Recognizing (MAR) T cell platform, which utilizes natural, non-genetically modified T cells to recognize and kill heterogeneous tumors. This approach is designed to provide durable anti-tumor responses with a favorable safety profile. Its lead product candidate, MT-601, recognizes six tumor-specific antigens and is being evaluated in a Phase 1 study for patients with lymphoma who have relapsed or are ineligible for anti-CD19 CAR-T cell therapy. The technology was originally developed at Baylor College of Medicine.

Recent filings

Filing Released Lang Actions
FORM 8-K
Board/Management Information Classification · 100% confidence The document is a Form 8-K filed with the SEC, which is a current report used to announce major events that shareholders should know about. The content specifically details the resignation of the Chief Financial Officer and termination of a related consulting agreement, which falls under Item 5.02 Departure of Directors or Principal Officers. There are no financial statements or detailed financial data included, and the document is not an annual or quarterly report, nor an earnings release. It is a regulatory filing announcing management changes. Therefore, the appropriate classification is 'MANG' for Board/Management Information.
2005-10-12 English
FORM 8-K
Board/Management Information Classification · 100% confidence The document is a Form 8-K filed with the SEC, dated September 30, 2005, reporting the departure of the company's President and CEO, Konstantine Sarafis. The key content is the resignation letter and related discussion about the CEO's departure and the company's search for a replacement. There are no financial statements or detailed financial data included. The primary focus is on management change, specifically the departure of a principal officer and director. According to the filing definitions, announcements of changes in the company's board of directors or senior management fall under Board/Management Information (MANG). The document is not an annual report, earnings release, or any other financial report type. Therefore, the correct classification is MANG with high confidence.
2005-09-30 English
FORM 10-QSB
Interim / Quarterly Report Classification · 100% confidence The document is titled 'FORM 10-QSB' and is a quarterly report pursuant to the Securities Exchange Act of 1934 for the quarterly period ended June 30, 2005. It contains detailed interim consolidated financial statements including balance sheets, statements of operations, cash flows, and notes to the financial statements. The document is approximately 15,000 characters long, indicating it is a full report rather than a brief announcement. The presence of unaudited interim financial statements and management discussion confirms it is a quarterly report. Therefore, the document fits the definition of an Interim / Quarterly Report (IR).
2005-08-19 English
NOTIFICATION OF LATE FILING
Regulatory Filings Classification · 100% confidence The document is a Form 12b-25 filed with the SEC, which is a Notification of Late Filing for a Form 10-Q quarterly report. It explains the reason for the delay in filing the quarterly report and states the expected filing date. The document does not contain actual financial data or the report itself but is a regulatory notification related to the filing process. According to the rules, such officer certifications or notifications about report filing delays should be classified as Regulatory Filings (RNS).
2005-08-15 English
FORM 10-QSB
Interim / Quarterly Report Classification · 100% confidence The document is titled 'FORM 10-QSB' and is a quarterly report pursuant to the Securities Exchange Act of 1934 for the quarterly period ended March 31, 2005. It contains detailed interim consolidated financial statements including balance sheets, statements of operations, cash flows, and notes to the financial statements. It also includes management's discussion and analysis, certifications by CEO and CFO, and other regulatory disclosures typical of a quarterly report. The length of the document (15,000 characters) and the presence of substantive financial data confirm it is the actual report, not just an announcement or certification. Therefore, this document fits the definition of an Interim / Quarterly Report (IR).
2005-05-23 English
NOTIFICATION OF LATE FILING
Regulatory Filings Classification · 100% confidence The document is a Form 12b-25, which is a Notification of Late Filing submitted to the SEC. It specifically states that the company, Genemax Corp., is notifying the SEC of a delay in filing its quarterly report on Form 10-Q for the period ended March 31, 2005. The document explains the reason for the delay and the expected filing date. It does not contain the actual financial statements or substantive financial data of the 10-Q report itself, but rather is a regulatory notification about the late filing. According to the rules, such a notification is classified as a Regulatory Filing (RNS) because it is a compliance document and not the report itself.
2005-05-16 English

Browse filings by year

28 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.